Can Peto\u27s paradox be used as the null hypothesis to identify the role of evolution in natural resistance to cancer? A critical review by Ducasse, Hugo et al.
  
 
 
 
Ducasse, Hugo, Ujvari, Beata, Solary, Eric, Vittecoq, Marion, Arnal, Audrey, Bernex, Florence, Pirot, Nelly, 
Misse, Dorothee, Bonhomme, Francois, Renaud, Francois, Thomas, Frederic and Roche, Benjamin 2015, Can 
Peto's paradox be used as the null hypothesis to identify the role of evolution in natural resistance to 
cancer? A critical review, BMC cancer, vol. 15, Article number: 792, pp. 1-9. 
 
DOI: 10.1186/s12885-015-1782-z 
 
 
 
 
 
 
 
This is the published version. 
 
©2015, The Authors 
 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
 
 
 
 
 
 
 
 
 
Available from Deakin Research Online: 
 
http://hdl.handle.net/10536/DRO/DU:30079910 
 
 
 
 
 
 
 
DEBATE Open Access
Can Peto’s paradox be used as the null
hypothesis to identify the role of evolution
in natural resistance to cancer? A critical
review
Hugo Ducasse1,2,3, Beata Ujvari4*, Eric Solary5*, Marion Vittecoq1,2,6, Audrey Arnal1,2, Florence Bernex2,3,7,8,
Nelly Pirot2,3,7,8, Dorothée Misse1,2, François Bonhomme9, François Renaud1,2, Frédéric Thomas1,2
and Benjamin Roche1,2,10
Abstract
Background: Carcinogenesis affects not only humans but almost all metazoan species. Understanding the rules
driving the occurrence of cancers in the wild is currently expected to provide crucial insights into identifying how
some species may have evolved efficient cancer resistance mechanisms. Recently the absence of correlation across
species between cancer prevalence and body size (coined as Peto’s paradox) has attracted a lot of attention.
Indeed, the disparity between this null hypothesis, where every cell is assumed to have an identical probability to
undergo malignant transformation, and empirical observations is particularly important to understand, due to the
fact that it could facilitate the identification of animal species that are more resistant to carcinogenesis than
expected. Moreover it would open up ways to identify the selective pressures that may be involved in cancer
resistance. However, Peto’s paradox relies on several questionable assumptions, complicating the interpretation of
the divergence between expected and observed cancer incidences.
Discussions: Here we review and challenge the different hypotheses on which this paradox relies on with the aim
of identifying how this null hypothesis could be better estimated in order to provide a standard protocol to study
the deviation between theoretical/theoretically predicted and observed cancer incidence. We show that due to the
disproportion and restricted nature of available data on animal cancers, applying Peto’s hypotheses at species level
could result in erroneous conclusions, and actually assume the existence of a paradox. Instead of using species level
comparisons, we propose an organ level approach to be a more accurate test of Peto’s assumptions.
Summary: The accuracy of Peto’s paradox assumptions are rarely valid and/or quantifiable, suggesting the need to
reconsider the use of Peto’s paradox as a null hypothesis in identifying the influence of natural selection on cancer
resistance mechanisms.
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Background
In the constant search for novel therapeutic strategies
against cancer, identifying and understanding natural
tumor suppressor mechanisms could provide promising
alternative avenues; nevertheless this area of research
still remains in its infancy [1–5]. While the human gen-
ome is being extensively explored for genes involved in
cancer initiation or progression [6–8], analysis of cancer
resistance in wildlife could also identify additional, previ-
ously overlooked, tumor suppressor mechanisms [9],
and concomitantly contribute to deciphering the under-
lying selective forces and evolutionary processes [10].
While almost all metazoan species are affected by cancer
[11–14] (Fig. 1), some animal species or individuals are
more at cancer risk than others [4, 9, 15, 16], suggesting
that resistance mechanisms have independently evolved
in distant lineages [3, 4, 17]. For example, while rodents
demonstrate a characteristically high prevalence of ma-
lignancies [18], cancer has never been observed in naked
mole-rats (Heterocephalus glaber) [19], not even in cap-
tivity, indicating that this species has developed efficient
tumor suppressor mechanisms during its evolution.
During the quest of identifying species with efficient
cancer resistance, a simplistic approach can be employed
[20–22]. Starting from the assumptions that carcinogen-
esis progresses via accumulation of mutations, and that
every cell division has an identical probability to gener-
ate these mutations, a simple prediction can be drawn:
large/long-lived animals should have more cancers than
smaller/shorter-lived ones, due to increased number of
cell divisions [3]. Actually, current evidence suggest that
large/long-lived animals tend to have, on average, similar
rates of cancer than small/short-lived ones [3]. A pos-
sible explanation for the absence of correlation, called
Peto’s paradox [3, 22], is that evolution via natural selec-
tion may have played a significant role in shaping resist-
ance mechanisms against malignant transformation in
large/long-lived species [3, 23, 24]. Peto’s paradox postu-
lates that animals that have evolved to be larger have
also developed mechanisms to offset the increased risk
of cancer. For example, some large vertebrate species
have numerous copies of tumor suppressor genes
(TSGs) [25], e.g. the elephant (Loxodonta africana) that
has twelve orthologues of the human p53 gene, a key
Fig. 1 Predicted cancer risk at different scales: between different species, between individuals from the same population, between organs in an
individual, and between cell types (purple cells are more at risk). From top to bottom: the different shapes represent theoretical species and
variation in cancer prevalence; the red crosses represent different indivuals of the same species and the number of tumors (e.g. centenarians in a
population). The third row illustrates the expected variation of tumor numbers among different organs (e.g. small intestine and large intestine).
The last row shows variation in cancer risk at the cellular scale (e.g. stem cells and differentiated cells).
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tumor suppressor fundamental to whole genome integ-
rity. The role of natural selection is reinforced by the
fact that Peto’s paradox seems not to exist at an intra-
specific level, where taller individuals seem to have
slightly more cancer than shorter ones [4, 16].
Although crucial to understand, this paradoxical rela-
tionship relies on a few over-simplistic assumptions
(hereafter defined as Peto’s hypotheses): (i) the number
of dividing-cells in an organism is strictly proportional
to its size, (ii) each dividing cell has the same risk of mu-
tation, and (iii) only mutations induce transformation to
malignancy. Supporting evidence for Peto’s hypotheses is
relatively scarce, mainly due to limited data on cancer
prevalence in the wild [26], as well as owing to the fact
that the existing evidence disproportionately focuses on
certain organs and/or animal species.
The simplicity of these hypotheses cast doubts on how
accurate/relevant/correct is Peto’s paradox in explaining
cancer resistance, when there is clear deviation from the-
oretical expectations to empirical data when considering
cancer prevalence in human and animal populations.
Therefore, we review here Peto’s hypotheses listed above,
through considering the complexity of carcinogenesis, as
well as by focusing on oncogenic processes at different or-
ganismal levels: cells, organs and populations. We show
that it is not only hard to accurately quantify the correct-
ness of Peto’s assumptions, but also that the hypotheses
are rarely valid, and therefore we propose to reconsider
the legitimacy of Peto’s paradox. We discuss in details the
potential ways to robustly assess the paradox, and argue
that apart from body size, additional ecological, envir-
onmental and behavioral factors, together with the
number of stem cells at the tissue/organismal levels
should also be considered when assessing cancer preva-
lence, and attempting to identify species with resistance
to cancer.
Discussion
Underlying hypotheses of Peto’s paradox
Do cell division patterns support Peto’s paradox?
The first hypothesis of Peto’s paradox postulates that
large/long-lived animals have more dividing cells com-
pared to smaller/short-lived ones. This hypothesis does
not take into account the great variety of division rates
within an organism where some cells could divide more
frequently than others.
In many, if not most, cases, cancer may arise from
transformation of stem cells [27], cells representing the
first step of differentiation processes and with a great
potential to divide (and/or proliferate). During the devel-
opment of multicellular organisms, the obvious function
of cell differentiation is to create new cell types. In adult
organisms, new cell types are no longer needed or pro-
duced – but cell replacement is essential, tissues could
be maintained by the self-duplication of fully mature
and functional cells. Therefore, the function of ongoing,
but tightly controlled cell differentiation may have
evolved to protect from detrimental cell-level progres-
sion [28, 29]. With such a serial differentiation pattern,
self-renewing cell populations are much more suscep-
tible to somatic mutation, but these cells are rare and
slow growing. Certain type of differentiated cells cannot
initiate propagation of malignant phenotypes because
they cannot divide, e.g. myocytes, adipocytes, and neu-
rons [30]. Based on that concept, Peto’s hypothesis
assumes that the number of stem cells should correlate
with body mass. But the number of stem cells as well as
the number of divisions have a low probability to correl-
ate with body mass. A different number of differentiated
cells may be obtained from the same number of stem
cells [31] by dint of a switch between proliferation (divid-
ing cell) and differentiation (non-dividing cell) (Fig. 2).
Then, the number of divisions will not only depend on the
number of stem cells, but also on the timing to switch be-
tween proliferation and differentiation (Fig. 2). The number
of cells that will divide as well as the tissue turnover
can be very different among organs [32], for example,
in humans, the intestinal epithelium completely self-
renews within ~ 5 days, while lung epithelium takes up
to 6 months to be replaced [28]. Furthermore the num-
ber of stem cells is also different among organs, and
this number could be involved in tumorigenesis [27].
Naively, one might think that having a larger organ re-
quires a greater number of cells, but recent perspective
papers show that differences of cell size could also be
essential in determining organ size [33]. Including cell
size as a parameter for the prediction of cancer risk
shows that the correlation between body/organ size and
cancer is weaker [33]. Furthermore, basal metabolic rate
(BMR) is also decreased in larger animals compared to
smaller ones (i.e. Max Kleiber allometric law [34]). Low
BMR induces less oxidative stress in comparison to
higher BMR [35]. Thus, larger animals could have a
lower level of oxidative stress compared to smaller
ones, and hence offsetting the higher cancer risk due
to increased cell numbers. Indeed, a recent study by
Dang, 2015 [36] support the hypothesis that metabolism
can drive tumorigenesis and accounts for Peto’s paradox
explanation.
Would transformation rates to cancer phenotypes be
equivalent across different cell and tissue types?
Another assumption of Peto’s paradox, based on the fact
that the rate of malignant transformation may be con-
stant and similar across cell types, is that the mutation
accumulation rate is constant among the cells. Import-
ant sources of genomic alterations are mutations, or
spontaneous errors of DNA replication, [37, 38] that
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occur despite the existence of a wide range of mecha-
nisms ensuring DNA repair and correct replication [39].
However, division processes – and mutation rates – may
differ among cell types: for instance mutation rate has
been reported to be 17 times higher in human somatic
cells than in germ cells [40]. The mutation rate may differ
also between organs, even though there is only limited
data available on the mutational spectra of various tissue
types [41]. Among differentiated cells, mutation rates of
human retina cells has been estimated to be 3.7 times
greater than intestinal epithelial cells, but still 1.48 times
lower compared to that observed in lymphocytes [40] in
which recombination events occur naturally and fre-
quently. The rate of genetic alterations also varies across
species, for example for a given organ, such as colon, mu-
tation rates per generation is 2.14 times greater in the rat
(Rattus norvegicus) than in the mouse (Mus musculus).
The level of genetic variation can be intrinsic to the tissue
type, e.g. the level of oxidative stress is very different across
different tissue types [35]. Furthermore, mutation rates
may also be affected by exposure to mutagens, especially
in tissues, such as skin, respiratory and digestive epithelia,
that are in direct contact with the external environment
and then naturally more exposed to mutagens and radia-
tions. Differences may also exist between similar organs in
diverse animal species [40].
As suggested above, additional mechanisms, especially
for lymphomas and leukemia, can increase DNA in-
stability in specific cell types such as T and B lympho-
cytes, some of the key cells of the vertebrate immune
system. One of the important characteristics of lympho-
cytes is that a specific part of their coding genome is
hypermutated to generate the incredible genetic diversity
necessary to recognize the plethora of foreign antigens,
and hence protect the organism from a broad range of
pathogens [42]. The enzymes involved in initiating the
hypermutation events could potentially also increase the
genomic instability of these cells and favor errors leading
to lymphoid transformation [43].
Would carcinogenesis rely on mutations only?
The last assumption of Peto’s paradox is that a variety of
somatic genomic alterations, from single nucleotide vari-
ants to larger structural aberrations (including insertions,
deletions, and chromosomal translocations) can contrib-
ute to cell transformation (somatic mutation theory [44]).
The genetic alterations will then be transmitted through
DNA replication and cell division to the daughter cells.
However, spontaneous mutations are insufficient to
Table 1 Main cancer causes apart from that mentioned in Peto’s
paradox
Genetic predisposition: heritable mutations that confer a higher
cancer risk, for instance mutations in BRCA1 and 2 genes associated
with 40–60 % cumulative risk of breast cancer [104].
Pathogens: some infectious agents like viruses, helminthes or bacteria
could also trigger tumor development. For instance, schistosomes have
been shown to induce bladder cancer, Human Papilloma Virus is
associated with cervical cancer or Helicobacter pylori (bacteria) increases
the risk of stomach cancer [87].
Pollutants: Pesticides, smoking or electromagnetic radiation are
associated with increased risk of cancer [105]. A study conducted by the
American Cancer Society shows that an increase of 10 micrograms per
cubic meter of fine particles in suspension would potentially cause an
8–14 % increase of lung cancer cases [106].
Alimentation: There is a positive correlation between obesity and
cancer mortality [107]. In fact obese people secret more leptine, a
hormone which in vitro stimulates cancer cell proliferation [108].
Fig. 2 Variation in time to switch between division and differentiation results in significant cell number differences inspite of the same starting
stem cell numbers. a Stop of proliferation and start of differentiation after three generations lead to a larger differentiated tissue mass. b Stop of
proliferation after one generation and start of differentiation earlier than A, result in a smaller differentiated tissue mass
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explain cell transformation in every situation [45–47], and
cancer can potentially also arise from a variety of other
mechanisms, which may vary between organs and species
(Table 1).
Variation in mutation numbers required to trigger
tumor formation and progress The number of genetic
alterations varies largely, depending on age and tumor
type, e.g. the number of genetic alterations is usually
reduced in pediatric tumors such as juvenile myelomo-
nocytic leukemia [48, 49] or acute megakaryoblastic
leukemia [50] while being the highest in lung cancers in-
duced by smoking [51] and melanomas induced by UV
[52, 53]. The genomic signature of tumor cells (established
based on the nature, localization and number of genomic
alterations identified in the affected cells) informs about
the factors that have promoted and contributed to the
malignant transformation (ageing versus toxic exposure
versus genetic predisposition etc…) [54–57]. Solid tumors
usually carry more genomic alterations than hematological
malignancies [58–60].
Furthermore, the functional consequences of a given
mutation are highly variable, depending on its nature
and localization in the genome. Those that have the most
striking effects are those that activate a proto-oncogene
(e.g. genes involved in cancer initiation/progression) or in-
activate a tumor suppressor gene (e.g. genes that allow
apoptosis or stop cell-cycle). A single nucleotide change
can be sufficient to transform a proto-oncogene into an
oncogene that induces cell transformation, whereas an
inhibiting mutation must affect the two alleles of a tumor
suppressor gene to favor transformation [61].
Epigenetic factors In addition, a growing number of
studies show that epigenetic stochasticity can act as driv-
ing force of carcinogenesis, via regulating the inhibition
of tumor suppressor genes [62] as well as the activation
of proto-oncogenes [63]. Since epigenetic stochasticity is
not correlated to body size, it may introduce background
noise when testing Peto’s paradox. Furthermore, since
environmental factors (e.g. species ecology, habitat, re-
source availability) can significantly influence transgenera-
tional epigenetic modifications, it can thus be important to
consider both consistent and stochastic (e.g. oil spills, fam-
ine, extreme climate parameters) environmental changes
across generations in order to decipher their contribution
to tumor formation [62].
Tumor microenvironment In addition to spontaneous
mutation and epigenetic mechanisms, it is also increas-
ingly recognized that tissue organization plays a major
role in the development of malignant phenotypes (tissue
organization field theory) [44]. This theory relies on the
fact that cancer cells can proliferate only within a
suitable microenvironment [1, 64], a particular tissue en-
vironment with specific conditions, e.g. low pH and/or
oxygen concentrations [65]. Generally, normal tissue
homeostasis and architecture inhibit progression of can-
cer, but changes in the microenvironment can shift the
balance of these signals to a cancer permissive state.
Tumor development, progression and metastasis are
strongly dependent on the microenvironmental condi-
tions met by cancer cells [1]. Tumor ecosystems consist
of non-malignant normal cells (fibroblasts, immune cells
and cells that comprise the blood vessels) and heteroge-
neous cancer cells, as well as their cellular products sup-
porting cancer cell growth. Interactions between cancer
cells and the surrounding microenvironment are con-
stant, and bidirectional. Tumors can influence the
microenvironment by releasing extracellular signals, pro-
moting tumor angiogenesis and inducing peripheral im-
mune tolerance. In return, the immune cells in the
microenvironment influence the growth and evolution
of cancerous cells (e.g. immune-editing [66]).
Animal models have demonstrated that alterations in
the tissue microenvironment can promote the emer-
gence of clonal malignancies, e.g. mutation in Dicer
genes (involved in RNA interference) generated in the
bone marrow microenvironment can promote the emer-
gence of a leukemic clone [67, 68]. Lastly, the recent
success of immunotherapeutic strategies demonstrates
that suppression of the anticancer immune response is
required for a tumor to emerge [69]. Therefore, even if
cells have enough mutations to initiate carcinogenesis,
malignant cells won’t develop without a permissive
cancer niche and immune system, which will be then
dependent of the tissue, the organ, and the species [65].
Thus, a Darwinian evolution of host factors relating to
resistance may be more relevant for an explanation of
Peto’s paradox, than carcinogenesis parameters such as
cell divisions or stem cell number.
Peto’s paradox at the population level: artifact or reality?
Sampling bias
Assessment of Peto’s paradox [3, 4, 12, 20] relies on can-
cer incidence measured over very few species, i.e., dog
(Canis lupus domesticus), mouse (Mus musculus), beluga
(Delphinapterus leucas) and humans [12], covering a
small gradient of the possible body mass. Another possible
bias, when assessing this paradox, is that the detection of
cancer relates only to the presence of macroscopic tu-
mors, and thus neglects the precancerous lesions or the
microscopic tumors of vital organs. Thus, due to the bias
of studied species, current datasets are definitely lacking
power to determine the exact relationship between body
mass and cancer incidence [70].
Additionally, other sampling biases may also explain
the lack of relationship between body mass and cancer
Ducasse et al. BMC Cancer  (2015) 15:792 Page 5 of 9
prevalence. Of particular concern is that research so far
has predominantly relied on domesticated and laboratory
animals when attempting to establish the correlation.
While the role of artificial selection for certain traits has
been recognized [71], it seems to also apply to the
emergence of cancer phenotypes. Anthropogenic selection
(including domestication and breeding for particular traits
in the laboratory) could have additionally led to artificial
selection for cancer resistance or susceptibility. Therefore,
laboratory and domesticated species, e.g., mice and dogs,
could have cancer incidences different from wildlife spe-
cies because of an inadvertent selection of traits involved
directly or indirectly with carcinogenesis.
Environmental factors triggering the development of cancer
phenotypes
Inter-species comparison can be challenging and mis-
leading due to the fact that cancer initiating factors are
probably not the same between different species. Indeed,
comparison between human and other species could be
biased by different levels and types of exposure to envir-
onmental and behavioral factors, including pollution,
abundant and excess food supply, and frequent contact
with mutagens [72, 73]. For instance, while there is no
significant difference between body size of roe deer
(Capreolus capreolus) and humans (on a logarithmic
scale), cancer incidence is much higher in humans (20 %
versus 2 % for roe deer) [74–76]. These different inci-
dences could be explained by physiological parameters,
but also by a differential exposure to mutagens. Further-
more, human cancers have been studied more exten-
sively and on a broader scale than the ones observed in
wildlife, i.e., roe deer. Similarly, although extensive data
is available on relatively high cancer prevalence in
Belugas (27 %), these numbers originate from a pod of
whales living in a polluted environment, suggesting that
cancer prevalence could also be overestimated for this
species, just like for humans [20]. For humans, the way
of life may be critically important, for instance low
concordance rate for leukemia in identical twins (5 %)
suggests that additional postnatal exposure should influ-
ence leukemia development [77].
Comparing animal species occupying different trophic
levels can also jeopardize the identification of animal
species with resistance to cancer. For instance, mutation
is also driven by cellular proliferation after injuries.
Therefore, species with high injury rate from predators
or aggressors should have evolved faster wound healing/
tissue regeneration [78, 79], which could concomitantly
increase the number of malignant transformations due
to increased level of cell proliferation being associated
with growth factors induced in tissue regeneration [80].
Furthermore, occupying different ecological niches can
also contribute to various levels of cancer prevalence.
For example, natural habitats of large mammals, such as
elephants or beluga whales (except the aforementioned
pod of whales), are significantly less polluted than the
habitat of benthic organisms that are more exposed to
contaminated sediments [81].
It is recognized that for many species longevity is
highly correlated with size [82], but there are also no-
ticeable exceptions, for instance the naked-mole rat that
displays a maximum lifespan of 28.3 years for a mass of
35 g (in contrast to a similar size Mus musculus with a
maximum lifespan of 3.5 years) [83]. Due to a long-lived
organism potentially accumulating more mutations
during its life [45, 84], it is expected that selection
will favor cancer resistance in small, but long-lived
species to circumvent the higher risk of cancer due to
mutation accumulation (e.g. naked mole rate [85, 86]).
Thus, for species displaying an atypical relationship
between size and longevity, cancer resistance pattern
will not follow the traditional prediction derived from
Peto’s paradox.
Finally, increasing number of studies suggest that at
least some cancers may have infectious origins [87]. The
number of pathogen known to be associated with cancer
in wildlife has also been on the rise, for example wood-
chucks (Marmota monax) suffering from hepatocarcino-
mas originating from hepatitis virus infections [88] and
marine turtles succumbing to fibropapillomatosis also
caused by viruses [89]. Several studies have focused on
comparative analysis of parasite communities, and on the
determining factors of parasite species richness, heterogen-
eity and densities [90–92]. A relationship between body size
and parasite species richness is thus possible, for example it
has been shown that endogenous retroviruses abundance
negatively correlates with body mass [93].
Summary
The disproportion and restricted nature of available data
can make a paradox seemingly exist despite the actual
lack of support for it. In this review, we have shown that
the hypotheses behind Peto’s paradox are rarely sup-
ported by evidence, and therefore we question the rele-
vance of using this paradox as a null hypothesis to
identify selective pressures shaping cancer resistance
mechanisms. Nevertheless, we emphasize that decipher-
ing the relationship between ecological and behavioral
parameters of animal species and cancer incidence can
be essential and important to the identification of species
which have evolved effective tumor resistance mechanisms.
In addition, given the recent paper by Tomasetti and
Vogelstein 2015 [27], we propose here that future research
on Peto’s paradox should be envisaged from the number of
stem cells per individuals/species rather than on the body
size which seems to be an unreliable surrogate.
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In this review, we have shown that having more cells
does not necessarily mean increased number of malig-
nant transformations, because different cell types have
different division rates, and DNA mutations can accu-
mulate at different frequencies through various mecha-
nisms. Thus, each organ and each species should have
different cancer prevalence. If organ size and tissue
environment were equivalent across species, then the
shortcomings of Peto’s hypotheses should not matter,
and Peto’s paradox would remain valid. However, reality
of animal species is obviously more complex due to
physiological, ecological and evolutionary constraints of
organisms.
Although Peto’s assumptions are not satisfied at cellu-
lar level, it is still possible to test Peto’s paradox across
species by considering cancer in each organ separately.
Due to individual organs having similar cellular structure
and micro-environment across different species, a cross-
species comparison of given organs would definitely be
more informative, and would allow more rigorous and
valid testing of Peto’s paradox.
However, the physiology of the organ should be
considered carefully. For instance, only focusing on a
digestive organ could lead to biased predictions due to
the size of digestive organs being strongly influenced by
diet (e.g. carnivore vs herbivore [94–97]), the digestive
tract of herbivores will be larger compared to carnivores,
to allow an optimal digestion of cellulose [98].
Another possibility is to focus on the genome size. In
fact, the variation observed in genome size across spe-
cies could provide the foundations to the principles of
Peto’s paradox (Animal Genome Size Database [99]): can-
cer incidence should be positively correlated with genome
size rather than body size. A bigger genome should induce
higher probability of mistakes in DNA replication during
cell division, leading to higher risk of mutation and con-
comitantly to cancer. It has been proposed that extremely
large genomes (like those of certain tree species) are an
adaptation to withstand somatic mutations over the long
haul, because of the mutagenic effects of pollutants, radia-
tions or transposable elements are diluted [100] inside
non-coding (and hence not harmful) junk DNA.
The philosophy of Peto’s paradox can be nevertheless
applied at different scales. Indeed, within a given species,
since each organ has its own tumor prevalence, one
could propose the existence of higher cancer risk for
larger organs [101] or, if Peto’s paradox exists at organ
level, a lower cancer risk could be associated with resist-
ance mechanisms driven by gene expression variations.
For instance, pancreas size is conditioned by the initial
number of progenitor cells. Therefore, size and cell
number of this organ are fixed for the rest of the life,
unlike the size/cell number of liver which could increase
over a lifetime [102].
If Peto’s paradox could only be applied to organs, one
should however also take into account that (i) the rate of
regeneration of organs can vary between individuals
depending on different exposure levels to mutagens (e.g.
organs involved in removal of toxic materials (kidney),
or organs in direct contact with external environment
(digestive organs, lung)), (ii) the different mutation rates
and (iii) the connections between the organs that may
influence the spread of metastases by predetermined
cellular pathways [103].
Conclusions
According to the different factors that may bias our in-
terpretation of Peto’s paradox, comparing cancer preva-
lence across different species should take into account
several fundamental parameters. Given that the assump-
tions of Peto’s paradox are not supported by strong
evidence, our review suggests alternative ways for a
more robust testing of the correlation (or rather lack of
it) between body size and cancer risk. First, in view of
great intra-individual variability in mutation and division
rates across organs, it would be more appropriate to
compare cancer prevalence in each organ separately
[20]. Furthermore, since environmental factors can dra-
matically influence carcinogenesis, the integration of
these factors would be essential to the accurate estima-
tion of cancer prevalence across species. For an effective
analysis, we suggest to compare species occupying simi-
lar ecological niches, or living in habitats where environ-
mental factors can be controlled for, such as zoos or
nature reserves.
We propose that refuting Peto’s paradox is actually
not the most important question to be answered. Rather,
investigating the lack of correlation between body mass
and cancer incidence (the foundation of Peto’s paradox)
opens up the opportunities to explore and answer such
important queries as to how the random appearance
of malignant cells influences cancer prevalence, and
whether we could identify tumor resistance mechanisms
without exploring entire genomes. The required next step
is thus to estimate correctly this null hypothesis in order
to interpret correctly this paradoxical relationship. Even if
the three Peto’s hypotheses are flawed, it is crucial to
determine whether the impact of discrepancies is enough
to explain the lack of correlation between cancer risk
and size/longevity at the interspecific level.
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